Cat.No：GM-87847AB
Product：Anti-DLL3-PBD(Dar2)[Rovalpituzumab tesirine]
Cat.No：GM-87847AB
Product：Anti-DLL3-PBD(Dar2)[Rovalpituzumab tesirine]
GM-87847AB-100 100μg
GM-87847AB-1mg 1mg
Expression System CHO
Purity >95% as determined by SDS-PAGE
Aggregation < 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR) 1.0-2.0
Endotoxin <1 EU/mg
Sterility 0.22 μm Filtered
Target DLL3
Clone Rovalpituzumab tesirine
Alternative Names SCDO1
Source/lsotype Monoclonal Human IgG1 (Delta 447K), kappa
Application Positive control of Cytotoxicity Assay
Description Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed specifically to target diseases with high expression of DLL3 (Delta-like ligand 3), with a particular focus on small cell lung cancer (SCLC). The mechanism of action of Rova-T combines the high specificity of the antibody with the potent cytotoxicity of its payload. By targeting DLL3 on the surface of tumor cells, Rova-T delivers its anticancer drug payload directly into these cells. Once Rova-T binds to DLL3 and is internalized by the tumor cell, the toxic payload (such as tesirine) is released, where it attaches to and damages the tumor cell’s DNA, causing double-strand breaks and ultimately triggering cell death. This design enables precise destruction of tumor cells while minimizing toxicity to normal tissues.
Formulation 20 mM Histidine, 100 mM NaCl, pH 6.0
Storage temp. Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
Cat.No：GM-87847AB
Product：Anti-DLL3-PBD(Dar2)[Rovalpituzumab tesirine]
GM-87847AB-100 100μg
GM-87847AB-1mg 1mg
Expression System CHO
Purity >95% as determined by SDS-PAGE
Aggregation < 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR) 1.0-2.0
Endotoxin <1 EU/mg
Sterility 0.22 μm Filtered
Target DLL3
Clone Rovalpituzumab tesirine
Alternative Names SCDO1
Source/lsotype Monoclonal Human IgG1 (Delta 447K), kappa
Application Positive control of Cytotoxicity Assay
Description Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed specifically to target diseases with high expression of DLL3 (Delta-like ligand 3), with a particular focus on small cell lung cancer (SCLC). The mechanism of action of Rova-T combines the high specificity of the antibody with the potent cytotoxicity of its payload. By targeting DLL3 on the surface of tumor cells, Rova-T delivers its anticancer drug payload directly into these cells. Once Rova-T binds to DLL3 and is internalized by the tumor cell, the toxic payload (such as tesirine) is released, where it attaches to and damages the tumor cell’s DNA, causing double-strand breaks and ultimately triggering cell death. This design enables precise destruction of tumor cells while minimizing toxicity to normal tissues.
Formulation 20 mM Histidine, 100 mM NaCl, pH 6.0
Storage temp. Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
